share_log
Reuters ·  Apr 29 18:30
Rhythm Pharmaceuticals Inc: Topline Data From Ongoing Pivotal Phase 3 Clinical Trial in Hypothalamic Obesity on Track for 2Q 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment